Basics uniQure N.V. Ordinary Shares uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. IPO Date: March 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $848.6M Activated in VL: True Average Daily Range Avg Daily Range: $0.64 | 2.91% Avg Daily Range (30 D): $0.64 | 4.71% Avg Daily Range (90 D): $0.57 | 4.49% Institutional Daily Volume Avg Daily Volume: .52M Avg Daily Volume (30 D): 2.07M Avg Daily Volume (90 D): 1.33M Trade Size Avg Trade Size (Sh.): 95 Avg Trade Size (Sh.) (30 D): 82 Avg Trade Size (Sh.) (90 D): 81 Institutional Trades Total Inst.Trades: 2,396 Avg Inst. Trade: $1.59M Avg Inst. Trade (30 D): $1.38M Avg Inst. Trade (90 D): $1.34M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.8M Avg Closing Trade (30 D): $1.93M Avg Closing Trade (90 D): $1.57M Avg Closing Volume: 91.83K         News Feb 7, 2025 @ 2:12 PM CSL Behring's Gene Therapy HEMGENIX® (etranacog... Source: Prnewswire Jan 7, 2025 @ 9:49 PM uniQure Announces Proposed Public Offering Source: N/A Aug 30, 2024 @ 12:59 PM Gene Therapy Market Size to Reach USD 54.39 Billio... Source: Sns Insider Jul 10, 2024 @ 12:01 PM Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.... Source: Avi Kapoor Jul 9, 2024 @ 4:11 PM Crude Oil Down 1%; Soligenix Shares Surge - Helen ... Source: Avi Kapoor Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.82 $-.91 Diluted EPS $-.82 $-.91 Revenue $ $ 1.57M $ 2.29M Gross Profit $ $ 1.37M $ 2.02M Net Income / Loss $ $ -43.64M $ -44.38M Operating Income / Loss $ $ -39.33M $ -40.23M Cost of Revenue $ $ .2M $ .26M Net Cash Flow $ $ 58.33M $ -37.96M PE Ratio